Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland  C. Orasch, O. Marchetti, J. Garbino, J. Schrenzel, S. Zimmerli, K. Mühlethaler, G. Pfyffer, C. Ruef, J. Fehr, R. Zbinden, T. Calandra, J. Bille  Clinical Microbiology and Infection  Volume 20, Issue 7, Pages 698-705 (July 2014) DOI: 10.1111/1469-0691.12440 Copyright © 2014 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 1 (a) Susceptibility of Candida blood isolates to fluconazole according to breakpoints applied. *No susceptible isolates (MIC ≤0.002 mg/L); 175 isolates with an MIC of 0.25–32 mg/L; 16 resistant isolates (MIC >32 mg/L). *CLSI breakpoints define dose-dependent susceptibility (MIC ≤32 mg/L) and resistance (MIC ≥64 mg/L), thus per definition there are no susceptible isolates of C. glabrata. (b) Susceptibility of Candida blood isolates to voriconazole according to breakpoints applied. *No CLSI and EUCAST breakpoints due to insufficient evidence. (c) Susceptibility of Candida blood isolates to caspofungin according to breakpoints applied. bp, breakpoint; CLSI, Clinical and Laboratory Standards Institute; EUCAST, European Committee on Antimicrobial Susceptibility Testing. Clinical Microbiology and Infection 2014 20, 698-705DOI: (10.1111/1469-0691.12440) Copyright © 2014 European Society of Clinical Infectious Diseases Terms and Conditions